Antihemophilic Factor (AHF, Factor VIII)



Antihemophilic Factor (AHF, Factor VIII)





(an tee hee moe fill’ ik fack’ tur)

Advate, Helixate FS, Hemofil M, Humate-P, Koate-DVI, Kogenate FS, Monoclate-P, Recombinate, ReFacto, Wilate, Xyntha

PREGNANCY CATEGORY C


Drug class

Antihemophilic


Therapeutic Actions

A normal plasma protein that is needed for the transformation of prothrombin to thrombin, the final step of the intrinsic clotting pathway.


Indications



  • Treatment of classical hemophilia (hemophilia A), in which there is a demonstrated deficiency of factor VIII; provides a temporary replacement of clotting factors to correct or prevent bleeding episodes or to allow necessary surgery


  • Short-term prophylaxis (ReFacto) to reduce frequency of spontaneous bleeding


  • Surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is ineffective or contraindicated to control bleeding; not for major surgery (Advate, Xyntha)


  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (Advate)




Available Forms

IV injection—250, 500, 1,000, 1,500, 2,000, 3,000 international units/vial in numerous preparations; 450, 900 units (Wilate)


Dosages

Adult and pediatric patients

Administer IV using a plastic syringe; dose depends on weight, severity of deficiency, and severity of bleeding. Follow treatment carefully with factor VIII level assays.

Formulas used as a guide for dosage are:


Jul 20, 2016 | Posted by in NURSING | Comments Off on Antihemophilic Factor (AHF, Factor VIII)

Full access? Get Clinical Tree

Get Clinical Tree app for offline access